O11 biomedical GmbH
also invests · investor profileMunich, DE · 1 known investors
Dimericon Therapeutics is a biotech company developing crosslinked helix dimers ("Dimericons") as therapeutics and as templates for small-molecule development, targeting hard-to-drug intracellular protein-protein interactions. Its lead program focuses on hematological malignancies, with a seed round supporting preclinical work toward an IND-ready clinical candidate.
Founders & leadership
Board
CL
DM
Investors · 1
Competitors · 2
by search overlap
Preqin3 shared keywordsPreqin provides private markets data, analytics, and benchmarking across private equity, venture capital, hedge funds, real estate, private credit, infrastructure, secondaries, and natural resources. Its products serve fund managers, investors, consultants, banks, and other financial professionals for fundraising, manager selection, due diligence, and performance analysis.
TipRanks3 shared keywordsFinancial analysis and stock research platform.
Companies competing with O11 biomedical GmbH for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does O11 biomedical GmbH do?
- Dimericon Therapeutics is a biotech company developing crosslinked helix dimers ("Dimericons") as therapeutics and as templates for small-molecule development, targeting hard-to-drug intracellular protein-protein interactions. Its lead program focuses on hematological malignancies, with a seed round supporting preclinical work toward an IND-ready clinical candidate.
- Who are O11 biomedical GmbH's investors?
- O11 biomedical GmbH's investors include CARMA FUND.
- Where is O11 biomedical GmbH headquartered?
- O11 biomedical GmbH is headquartered in Munich, DE.